CF cystic fibrosis COPD chronic obstructive pulmonary disease EFS electrical field stimulation FDA Food and Drug Adminstration FEV1 forced expiratory volume in1 second LPS lipopolysaccharide PDE phosphodiesterase 1 INTRODUCTION Current treatment of patients with asthma or chronic obstructive pulmonary disease (COPD) predominantly involves the use of inhaled bronchodilators (β2-adrenoceptor agonists and muscarinic receptor antagonists)(Matera et al., 2020) and anti-inflammatory corticosteroids...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Clive Page
Handbook of Experimental Pharmacology
The is one of the most authoritative and influential book series in pharmacology. It provides critical and comprehensive discussions of the most significant areas of pharmacological research, written by leading international authorities. Each volume in the series represents the most informative and contemporary account of its subject available, making it an unrivalled reference source. HEP is indexed in Medline/PubMed and Scopus.
Lung Function Changes and Connective Tissue Growth Factor Expression in Idiopathic Pulmonary Fibrosis, Other Progressive Fibrosing Interstitial Lung Diseases, and Post-COVID Fibrosis
Specialty Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional.
Drug-drug interactions and synergy: from pharmacological models to clinical application
Abstract This review explores the concept of synergy in pharmacology, emphasizing its importance in optimizing treatment outcomes through the combination of drugs with different mechanisms of action. Synergy, defined as an effect greater than the expected additive effect elicited by individual agents according to specific predictive models, offers a promising approach to enhance therapeutic efficacy while minimizing adverse events.
What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials
M Cazzola reports receiving grants and personal fees from Verona Pharma. M Cazzola and L Calzetta have patents 9717732, 9700558, 20160008363, 20160000790 and 20170266190 licensed to Verona Pharma. C Page reports receiving grants and personal fees from, and holds equity in, Verona Pharma. D Singh reports personal fees from Verona Pharma.
Novel Anti-Inflammatory Approaches to COPD
Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 18 Authors Cazzola M , Hanania NA, Page CP, Matera MG Received 27 April 2023 Accepted for publication 20 June 2023 Published 29 June 2023 Volume 2023:18 Pages 1333—1352 DOI https://doi.org/10.2147/COPD.S419056 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Jill Ohar Mario Cazzola,1 Nicola A Hanania,2 Clive P Page,3 Maria...
Ensifentrine: A First-in-class Bifunctional Drug for the Treatment of Chronic Obstructive Pulmonary Disease
COPD Read Time: 10 mins Published Online: December 9th 2022 touchREVIEWS in Respiratory & Pulmonary Diseases. 2022;7(2):48–53 Authors: Mario Cazzola, Clive Page, Maria Gabriella Matera Abstract: Overview Ensifentrine is an inhaled ‘bifunctional’ dual phosphodiesterase 3/4 inhibitor that exhibits both bronchodilator and anti-inflammatory activities.
MA's Free Guide to (Mostly) Free Streams, Feb. 22-March 1
We will be updating this list weekly. Please note that all times are given in U.S. Eastern Time (ET). To calculate in other time zones or counties, British Summer Time (BST) is currently five hours ahead of ET and Central European Time (CET) is currently six hours ahead. U.S. Central Daylight Time (CDT) is one hour behind ET. Mountain Time (MT) is two hours behind ET, while Pacific Time (PT) is three hours behind. Contact editor@musicalamerica.com.
Sex differences in the influence of obesity on a murine model of allergic lung inflammation
Email or Customer ID "Please check your email for instructions on resetting your password. If you do not receive an email within 10 minutes, your email address may not be registered, and you may need to create a new Wiley Online Library account.
An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD
RPL554 is a novel inhaled dual phosphodiesterase (PDE)3/4 inhibitor that has been developed with the goal of having “bifunctional” bronchodilator and anti-inflammatory activities in a single molecule [1, 2].
Sir David Jack: an extraordinary drug discoverer and developer
Sir David Jack, FRS, was a remarkable man, driven by altruistic intent, a passionate and exceptional scientist, who was able to apply the full power of his impressive intellect to the discovery of new and important medicines for the benefit of patients in need.
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis
AbstractIn order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis and chronic obstructive pulmonary disease (COPD), we have carried out a meta-analysis testing the available evidence that NAC treatment may be effective in preventing exacerbations of chronic bronchitis or COPD and evaluating whether there is a substantial difference between the responses induced by low (?600?mg per day) and high (>600?mg per day) doses of NAC.The...
A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD | European Respiratory Society
AbstractUnfractionated heparin (UFH) is a drug with a structurally diverse molecular scaffold naturally oriented to multiple targets.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Clive
Contact Clive, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack